Uptake of an antiplasmodial protease inhibitor into Plasmodium falciparum-infected human erythrocytes via a parasite-induced pathway.
Saliba
K J
KJ
Division of Biochemistry and Molecular Biology, Faculty of Science, Australian National University, Canberra ACT.
Kirk
K
K
D000818:Animals; D000962:Antimalarials / Q000378:metabolism / Q000494:pharmacology; D001692:Biological Transport; D002738:Chloroquine / Q000378:metabolism / Q000494:pharmacology; D004912:Erythrocytes / Q000378:metabolism* / Q000469:parasitology*; D005665:Furosemide / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D010436:Pepstatins / Q000378:metabolism* / Q000494:pharmacology; D010963:Plasmodium falciparum / Q000187:drug effects / Q000378:metabolism*; D011480:Protease Inhibitors / Q000378:metabolism* / Q000494:pharmacology
D000962:Antimalarials; D010436:Pepstatins; D011480:Protease Inhibitors; C014195:Streptomyces pepsin inhibitor; D005665:Furosemide; D002738:Chloroquine; C031375:pepstatin